OKYO Pharma LtdOKYO
Price (close)
$1.38
Market cap
$72.4M
P/E
—
Revenue (FY)
—
Net income
-$4.7M
Dividend yield
—
1-year total return
-37.8%
Net margin
—
Revenue growth
—
Debt / equity
—
What OKYO Pharma Ltd does.
are a clinical-stage ophthalmology company focused on developing differentiated therapies for corneal and anterior segment diseases.
The Company is committed to addressing significant unmet medical needs in corneal and anterior segment diseases through innovative science,
extensive ophthalmology expertise across research, clinical development, regulatory affairs, and commercialization, we are advancing
Revenue and profit, by fiscal year.
| Fiscal year | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|
| Net income | -$1.5M | -$3.4M | -$5.4M | -$13.3M | -$16.8M | -$4.7M |
| Free cash flow | — | -$1.6M | -$5.5M | -$7.7M | — | -$1.8M |
More on OKYO.
- OKYO Pharma Ltd summary
- OKYO Pharma Ltd financial statements
- OKYO Pharma Ltd key metrics
- OKYO Pharma Ltd health scores and style box
- OKYO Pharma Ltd earnings
- OKYO Pharma Ltd dividends
- OKYO Pharma Ltd valuation
- OKYO Pharma Ltd ownership and insiders
- OKYO Pharma Ltd peers
Figures from OKYO Pharma Ltd's filings with the U.S. SEC, standardised automatically; prices are end-of-day closes. Not financial advice.